Edgewise Therapeutics Price Target Raised to $59 on Positive HCM Trial Data

Edgewise Therapeutics, Inc. (EWTX) has had its price target raised to $59 by analysts following positive data from its HCM (Hypertrophic Cardiomyopathy) trial.